MétaCan
Menu
Back to cohort
Record W2911899081 · doi:10.1093/ecco-jcc/jjy222.634

P510 Infliximab in the very young: it is all about the dosing – a multi-centre study

2019· article· en· W2911899081 on OpenAlexaffabout
M Jongsma, Dwight A. Winter, Hoang-Long C. Huynh, Lorenzo Norsa, Séamus Hussey, K‐L Kolho, Jiří Bronský, Amit Assa, Shlomi Cohen, Raffi Lev‐Tzion, Stéphanie Van Biervliet, T de Meij, Daniel Shouval, Eytan Wine, Victorien M. Wolters, Antoine Christiaens, Christine Martinez‐Vinson, Lissy de Ridder

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunodeficiency and Autoimmune Disorders
Canadian institutionsChild, Adolescent and Family Mental Health
Fundersnot available
KeywordsMedicineInfliximabInflammatory bowel diseaseDosingTherapeutic drug monitoringInternal medicineThiopurine methyltransferaseRegimenTrough levelPopulationYoung adultPediatricsPharmacokineticsDiseaseTransplantation

Abstract

fetched live from OpenAlex

Infliximab (IFX) is administered intravenously using weight-based dose (5 mg/kg) in paediatric and adult inflammatory bowel disease (IBD) patients. However, previous IFX pharmacokinetic (PK) data suggest this results in lower mean serum IFX concentrations in paediatric compared with adult CD patients, especially in young patients. We hypothesise that young children need a more intensive treatment regimen than the current weight-based dose administration. To assess IFX PK, based on existing therapeutic drug monitoring (TDM) data in a population of paediatric IBD patients below age of 10 and to compare these to paediatric IBD patients above age of 10. TDM data were collected retrospectively in 15 European and Canadian centres. Children treated with IFX between 2004–2016 were included, if IFX was started as IBD treatment below 10 year and PK data were available. These data were compared with a control group of paediatric IBD patients above age of 10 with PK data of IFX treated paediatric IBD patients in the Erasmus MC-Sophia Children’s Hospital. One-hundred and sixty paediatric IBD patients were eligible for the study (110 < 10 year; 50 >10 year). Median age IFX treatment was started was 8.3 years [IQR 6.9–8.9] in the young patients (YP), in the older patient (OP) group this was 14.3 [IQR 12.6–15.6]. In 49% of the YP trough levels were below therapeutic range (<3 μg/ml) at 14 weeks. The median interval between IFX infusions was significantly shorter (median interval days 49[39–56] vs. 56[55–56]; p < .001), while the dose (median dose 8 [5–10] mg/kg vs. 5 [5–8.5] mg/kg; p = 0.013) was significantly higher in the YP than OP at 1 year of scheduled IFX maintenance treatment. Moreover, significantly more YP developed antibodies to infliximab (ATI) during follow-up (44% in YP vs. 8.7 in OP, p = 0.004) compared with the OP group, while overall duration of response to IFX was not significantly different between both age groups (after 2 years 53%(n = 29) in YP vs. 63%(n = 26) in OP; p = 0.24). To achieve therapeutic IFX trough levels in young paediatric IBD patients (<10 years) a more intensive treatment schedule is required. Sub therapeutic IFX levels may be the explanation for development of more ATI’s in young patients compared with the older ones. Despite more ATI formation, duration of IFX therapy was comparable for both age groups. IFX dosing in YP is frequently suboptimal. We recommend to start with a higher dose IFX and an induction schedule with shorter intervals between infusions, beside use of early TDM to further personalise IFX treatment in young IBD patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.259
Teacher spread0.244 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicImmunodeficiency and Autoimmune DisordersFrench-language works237,207